Drugmaker Lupin’s shares fell as much as 3.8 per cent to ₹ 835, their biggest daily percentage drop since March 18.
It has received letter from the US FDA classifying the inspection conducted at Pithampur unit-2 facility in January as official action indicated.
The regulator has stated that the facility may be subject to regulatory or administrative action.
On Wednesday, over 718,720 shares changed hands in early trade, compared with 30-day average volume of 2.27 million.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.